Febuxostat Viatris 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IG/1688 
A.2.a - Administrative change - Change in the 
15/01/2024 
(invented) name of the medicinal product for CAPs 
IB/0019 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/05/2023 
generic/hybrid/biosimilar products following 
SmPC, 
Labelling and 
PL 
SmPC 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0018/G 
This was an application for a group of variations. 
24/04/2023 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
SmPC, 
Labelling and 
PL 
N/0017 
Minor change in labelling or package leaflet not 
27/03/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0016/G 
This was an application for a group of variations. 
16/02/2023 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0015 
C.I.z - Changes (Safety/Efficacy) of Human and 
30/09/2022 
24/02/2023 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
IB/0014 
C.I.2.a - Change in the SPC, Labelling or PL of a 
26/04/2022 
24/02/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II/0012 
B.I.z - Quality change - Active substance - Other 
24/03/2022 
n/a 
variation 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/03/2022 
24/02/2023 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
R/0011 
Renewal of the marketing authorisation. 
16/12/2021 
16/02/2022 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Febuxostat Mylan in the approved indication remains 
favourable and therefore recommended the renewal of the 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
marketing authorisation with unlimited validity. 
T/0010 
Transfer of Marketing Authorisation 
11/08/2021 
22/09/2021 
SmPC, 
Labelling and 
PL 
IAIN/0009 
B.II.b.2.c.1 - Change to importer, batch release 
23/04/2020 
25/11/2020 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0008 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/12/2019 
25/11/2020 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IA/0006 
B.II.b.2.a - Change to importer, batch release 
06/05/2019 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
N/0005 
Minor change in labelling or package leaflet not 
13/03/2019 
06/06/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0004/G 
This was an application for a group of variations. 
14/01/2019 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
IB/0003/G 
This was an application for a group of variations. 
16/11/2018 
06/06/2019 
SmPC, 
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
B.II.e.5.a.1 - Change in pack size of the finished 
Labelling and 
PL 
Page 5/8 
 
 
 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
Page 6/8 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IB/0002 
Update of sections 4.4,4.5 and 5.3 of the SmPC in 
12/09/2018 
06/06/2019 
SmPC and PL 
order to reflect the results of preclinical study MRPO-
2015-PKM-005 “Pharmacokinetic of azathioprine in 
the rat after one-week daily oral treatment at three 
different dosages and with the concomitant oral 
administration of febuxostat or allopurinol" and 
clinical study REP-POPPK-MRP-2015-PKM-005 
“population pharmacokinetic analysis from study 
titled pharmacokinetic of azathioprine in the rat after 
one-week daily oral treatment at three different 
dosages and with the concomitant oral 
administration of febuxostat or allopurinol”,  
investigating the drug-drug interaction with 
azathioprine when co-administered with febuxostat. 
The Package Leaflet has been adapted accordingly. 
Page 7/8 
 
 
 
 
 
 
 
The changes are performed in line with the reference 
product. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0001 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
28/06/2018 
06/06/2019 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
